Clinigen Licenses Commercialization Rights for Proleukin from Novartis in the US

 Clinigen Licenses Commercialization Rights for Proleukin from Novartis in the US

Clinigen Licenses Commercialization Rights for Proleukin from Novartis in the US

Shots:

  • Novartis to receive $210M as total deal value, including $120M upfront, $60M deferred payment for 12mos. and $30M milestone on sales of product. Clinigen to get commercialization rights for Novartis’ Proleukin in the US and WW license for Proleukin
  • The focus of the agreement is to develop and commercialize Proleukin and strengthen Clinigen’s immune-oncology portfolio with expansion of footprints in the US
  • Proleukin (aldesleukin, human recombinant IL-2) is a synthetic protein acts similarily as nterleukin-2 (IL-2) involved in activating WBCs and is being evaluated in 80 trials in the US for multiple therapy areas

Click here to read full press release/ article | Ref: Clinigen | Image: Pharmacy Research UK

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post